Scarica l'app Stockscreener
4.79
1.24%
-0.06
Dopo l'orario di chiusura:
4.76
-0.03
-0.63%
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Brokers Set Expectations for VNDA Q3 Earnings - MarketBeat
Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN
Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance
Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat
StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance
Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance
D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace
Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters
Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch
Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance
Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com
Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals - WHBL
Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid By Investing.com - Investing.com UK
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. - PR Newswire
Vanda Pharma stock soars as Cycle Pharma reiterates $8/share offer - Seeking Alpha
Cycle Pharmaceuticals offers $8 per share for Vanda By Investing.com - Investing.com UK
Cycle Pharma Is Said to Stand By $488 Million Offer for Vanda - AllSides
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million. - Marketscreener.com
Profit Investment Management LLC Lowers Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Squarepoint Ops LLC Decreases Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.
US Supreme Court reportedly declines to hear Vanda patent case - MSN
Dimensional Fund Advisors LP Purchases 292,172 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Sei Investments Co. Sells 123,694 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings By Investing.com - Investing.com Canada
Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings - Investing.com India
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):